BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids, originally derived from a naturally occurring protein fragment in gastric tissue

animal studies suggest it may support healing of gastric ulcers and damaged intestinal lining Preclinical models suggest it may help modulate inflammation, though this has not been established in controlled human trials Known risks and side effects: Because it is sold as an unregulated research chemical rather than a manufactured pharmaceutical, product purity and dosing accuracy cannot be verified, and the FDA has flagged potential impurities and manufacturing-quality concerns FDA's Category 2 determination specifically cited potential immune reactions and hypersensitivity as a safety concern User-reported (non-clinical-trial) effects include injection-site irritation, redness, or swelling, along with occasional headache, nausea, or lightheadedness, based on anecdotal reporting rather than controlled studies No long-term human safety data exists

Treatment of HUVECs with BPC-157 (1 g/mL, 5 g/mL, and 10 g/mL) enhanced cell motility in a concentration-dependent manner compared with untreated cells
In most regions, you cannot simply walk into a pharmacy and buy it
This often makes oral supplements insufficient
Furthermore, results showed significant enrichment of GO terms related to cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) activity